A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
Unknown

Flash Digest: News i

By Jaehwan Park - Edited by Kayla Haran Bipartisan Lawmakers Introduce ...

13399-surveillance_news

Second Circuit Prohi

By Filippo Raso – Edited by Shailin Thomas Microsoft v. US, ...

infringement

U.S. District Court

By Emily Chan – Edited by Evan Tallmadge In re TC ...

Senate

Congresswoman Speier

By Priyanka Nawathe – Edited by Henry Thomas H. R. Bill ...

Photo By: Robert Scoble - CC BY 2.0

Oracle Renews Motion

[caption id="attachment_3907" align="alignleft" width="175"] Photo By: Robert Scoble - CC ...